|
시장보고서
상품코드
1624419
일회용 바이오리액터 시장 규모 : 지역별, 범위 및 예측Single-use Bioreactors Market Size By Product, By Cell, By Molecule, By End-User, By Geographic Scope And Forecast |
||||||
일회용 바이오리액터 시장 규모는 2023년 43억 7,000만 달러로 평가되며, 2024년부터 2031년까지 연평균 19.26% 성장하여 2031년에는 179억 달러에 달할 것으로 예상됩니다. 일회용 바이오리액터 시장은 바이오 공정 산업에서 다양한 바이오의약품 및 생명공학 응용 분야에 대한 일회용 바이오리액터 시스템의 개발, 제조 및 활용에 초점을 맞춘 부문을 의미합니다. 이러한 시스템은 세포 증식, 발효, 단백질 발현과 같은 세포배양 공정에 효율적이고 비용 효율적인 솔루션을 제공하면서 기존의 스테인리스 스틸 바이오리액터의 필요성을 최소화하도록 설계되었습니다.
생물학적 제제 수요 증가:
다양한 만성질환의 치료 및 관리에 효과적인 생물학적 제제 및 바이오시밀러에 대한 세계 수요의 급증은 일회용 바이오리액터 시장의 주요 촉진요인입니다. 이러한 반응기는 생물학적 제제 제조를 위한 비용 효율적이고, 다재다능하며, 보다 신속한 솔루션을 제공하여 의약품에 대한 수요 증가에 부응하고 있습니다.
비용 효율성 및 오염 위험 감소:
일회용 바이오리액터는 의약품 제조에서 중요한 교차 오염의 위험과 고도의 멸균 기술의 필요성을 줄여줍니다. 일회용이기 때문에 세척, 유지보수 및 다운타임에 대한 비용을 절감할 수 있어 조직에 경제적으로 실행 가능한 선택이 될 수 있습니다.
유연성 및 확장성:
일회용 바이오리액터는 대규모 설비 투자가 필요하지 않고, 파일럿에서 상업 생산에 이르기까지 다양한 생산 규모에 대응할 수 있는 다재다능함이 그 적용을 촉진하고 있습니다. 이러한 적응성은 바이오의약품 연구 개발의 역동적인 요구에 대응하고, 신속한 운영 확장을 가능하게 하며, 시장 개척을 촉진합니다.
기술의 발전과 규제 지원:
바이오리액터 설계, 재료 및 센서 기술의 지속적인 개발로 바이오 공정의 효율성과 제어가 향상되고 있습니다. 규제 당국의 임상 및 상업적 제조를 위한 일회용 시스템 승인은 산업 표준 준수를 보장함으로써 시장 성장에 기여하고 있습니다.
주요 과제:
폐기물 관리 및 환경 문제:
일회용 바이오리액터의 일회성 사용은 플라스틱 쓰레기 발생으로 인한 심각한 환경 문제를 야기합니다. 이 폐기물은 제약 산업과 생명공학 산업이 환경 지속가능성을 중시하는 것과 모순되기 때문에 책임감 있게 관리하기 어렵고, 시장 수요를 저해하고 있습니다.
규모의 한계:
일회용 바이오리액터는 특정 생산 규모에서는 유연하고 비용 효율적이지만, 대규모 바이오 제조에 있어서는 한계가 있습니다. 대용량이 요구되기 때문에 일회용 시스템은 더 이상 실용적이지 않으며, 대량의 생물학적 공정에서 사용이 제한될 수 있습니다.
재료 적합성 및 용출물:
일회용 바이오리액터에 사용되는 재료는 다양한 바이오 공정에 적합하고 제품과 바람직하지 않은 상호 작용을 일으키지 않아야 합니다. 생물학적 제제를 오염시킬 수 있는 용출물이나 추출물은 제품의 순도와 안전성을 유지하는 데 큰 장애물이 되어 산업의 확장을 제한하고 있습니다.
주요 동향:
세포 및 유전자 치료로 확대:
일회용 바이오리액터는 세포 치료와 유전자 치료가 치료의 주류로 떠오르면서 그 제조에 점점 더 많이 사용되고 있습니다. 적응성이 높고 오염 위험이 낮기 때문에 이러한 의약품에 요구되는 정밀하고 섬세한 제조 공정에 적합합니다.
지속가능성을 위한 노력:
환경 문제에 대한 우려로 인해 보다 지속가능한 일회용 바이오리액터 시스템을 만들려는 움직임이 증가하고 있습니다. 여기에는 사용한 재료의 재활용, 일회용품의 탄소 배출량 최소화, 환경에 미치는 영향을 줄이기 위한 생분해성 또는 환경 친화적인 대체품 개발 등의 시도가 포함됩니다.
커스터마이징 및 확장성 솔루션:
개발 기업들은 소규모 R&D에서 대규모 상업 생산에 이르기까지 다양한 제조 요건을 충족하는 맞춤형 솔루션을 제공하는 데 주력하고 있습니다. 이러한 맞춤형 및 확장 가능한 일회용 바이오리액터 설정에 대한 이러한 추세는 바이오 제약 기업의 다양한 요구를 충족시키고 광범위한 응용을 가능하게 합니다.
Single-use Bioreactors Market size was valued at USD 4.37 Billion in 2023 and is projected to reach USD 17.9 Billion by 2031, growing at a CAGR of 19.26% from 2024 to 2031. The Single-use Bioreactors Market refers to the segment within the bioprocessing industry that focuses on the development, manufacturing, and utilization of single-use bioreactor systems for various biopharmaceutical and biotechnology applications. These systems are designed to provide efficient and cost-effective solutions for cell culture processes, including cell growth, fermentation, and protein expression, while minimizing the need for traditional stainless steel bioreactors.
The key market dynamics that are shaping the single-use bioreactors market include:
Increasing Demand for Biologics:
The global spike in demand for biologics and biosimilars, which are effective in treating and managing a variety of chronic diseases, is a major driver of the single-use bioreactors market. These reactors provide a cost-effective, versatile, and speedier solution for biologics manufacturing, meeting the growing need for medicinal pharmaceuticals.
Cost Efficiency and Lower Contamination Risks:
Single-use bioreactors decrease the need for sophisticated sterilization techniques and the risk of cross-contamination, which is critical in pharmaceutical manufacturing. Their disposability results in cost savings on cleaning, maintenance, and downtime, making them an economically viable option for organizations.
Flexibility and Scalability:
The versatility of single-use bioreactors to various production sizes, from pilot to commercial, without requiring major capital investment, drives their application. This adaptability meets the dynamic needs of biopharmaceutical research and development, enabling quick scaling of operations and propelling market growth.
Technological Advancements and Regulatory Support:
Continuous developments in bioreactor design, materials, and sensor technology improve bioprocess efficiency and control. The approval of single-use systems for clinical and commercial manufacturing by regulatory organizations contributing to market growth by assuring compliance with industry standards.
Key Challenges:
Waste Management and Environmental Concerns:
The disposability of single-use bioreactors presents serious environmental problems due to the production of plastic trash. This waste is difficult to manage responsibly because it contradicts the pharmaceutical and biotech industries' growing emphasis on environmental sustainability, inhibiting the market demand.
Limitations in Scale:
While single-use bioreactors are flexible and cost-effective for particular scales of production, they have limitations when it comes to large-scale biomanufacturing. The requirement for bigger volumes makes single-use systems less practicable, potentially limiting their use in high-volume biologic processes.
Material Compatibility and Leachables:
The materials used in single-use bioreactors must be suitable with a wide range of bioprocesses and have no unfavorable interactions with the product. The concerning leachables and extractables that could contaminate biologic goods present significant hurdles to maintaining product purity and safety, limiting industry expansion.
Key Trends:
Expansion into Cell and Gene Therapies:
Single-use bioreactors are being used more and more in the manufacturing of cell and gene therapies as they become mainstream medical treatments. Their adaptability and low contamination risk make them perfect for the precise and sensitive manufacturing processes required by these medicines.
Sustainability Initiatives:
In response to environmental concerns, there is a rising movement to create more sustainable single-use bioreactor systems. This involves attempts to recycle used materials, minimize the carbon footprint of disposables, and develop biodegradable or eco-friendly alternatives that aim to lessen environmental effects.
Customization and Scalability Solutions:
Manufacturers are focusing on delivering customized solutions that meet unique manufacturing requirements, ranging from small-scale research and development to large-scale commercial production. This trend towards customizable and scalable single-use bioreactor setups meets the different needs of biopharmaceutical firms, enabling a wide range of applications.
Here is a more detailed regional analysis of the single-use bioreactors Market:
North America:
According to Verified Market Research, North America is estimated to dominate in single-use bioreactors market over the forecast period. North America, particularly the United States, has a thriving and advanced biopharmaceutical industry that leads in biologics and vaccine production. This industry's strength provides a sizable client base for single-use bioreactors, promoting their usage in flexible, cost-effective, and efficient biomanufacturing processes.
The region's strong investment in R&D, which is supported by both the commercial and public sectors, drives innovation in bioprocessing technology. This investment promotes the use of single-use bioreactors, which are essential for the development and production of next-generation biopharmaceuticals.
The strict regulatory framework in North America, which focuses on product safety and manufacturing efficiency, promotes the usage of single-use bioreactors. These systems provide advantages in terms of compliance, reduced contamination risk, and scalability, while also meeting regulatory agencies' quality assurance standards for pharmaceutical manufacturing.
Furthermore, North America has been at the forefront of introducing new technology into biomanufacturing, such as single-use bioreactors. The region's openness to embrace innovation promotes operational efficiencies, shorter production timelines, and cheaper prices, cementing its dominance in the global market for single-use bioreactors.
Asia Pacific:
The biopharmaceutical industry in the Asia Pacific is growing quickly, fueled by a rise in investments in biotech startups and the regional growth of multinational pharmaceutical corporations. This expansion increases demand for single-use bioreactors, which provide flexibility and efficiency in biologics production.
Many nations in the Asia Pacific are enacting supporting laws and providing funds to grow their biotech industry. Government attempts to improve healthcare infrastructure, promote R&D, and attract foreign investment all contribute to the growing need for single-use bioreactors.
Furthermore, the region's huge and ageing population, combined with expanding healthcare awareness and expenditure, is driving up demand for biopharmaceuticals. Single-use bioreactors, which are essential for the quick manufacture of vaccines and biologics, are increasingly being used to address these healthcare demands efficiently.
Europe:
Europe is experiencing tremendous investment in biopharmaceutical research and development from both the public and private sectors. This funding promotes innovation in bioprocessing technologies, such as single-use bioreactors, thereby facilitating their application in the development and manufacturing of improved medicinal solutions.
European regulatory organizations have backed innovative manufacturing technologies that promise to improve product quality and safety. This regulatory environment pushes pharmaceutical companies to deploy single-use bioreactor systems, which increase sterility and reduce contamination risk while adhering to regulatory requirements.
Furthermore, the increased emphasis on sustainability and decreasing environmental footprints in European manufacturing promotes the usage of single-use bioreactors. Despite waste concerns, the overall environmental impact is offset through lower energy and water consumption, which is consistent with the region's sustainability goals.
The Single-use Bioreactors Market is segmented based on Product, Cell, Molecule, End-User, And Geography.
Based on Product, the market is segmented into Bioreactor Systems, Media Bags, Filtration Assemblies and Others. The bioreactor systems segment is estimated to dominate the single-use bioreactors market due to the critical role that these systems play in cell culture and biopharmaceutical synthesis. Single-use bioreactor systems provide substantial benefits, such as reduced contamination risk, lower initial investment, and shorter batch turnaround times, which are especially useful in the fast-paced pharmaceutical and biotech sectors. Their scalability and flexibility make them appropriate for a wide range of applications, from small-scale R&D to large-scale commercial manufacturing.
Based on Cell, the market is segmented into Mammalian Cells, Bacteria, Yeast and Others. The mammalian cell segment is estimated to dominate the single-use bioreactors market due to the important role mammalian cells play in the synthesis of complex biologics such as monoclonal antibodies, vaccines, and recombinant proteins. These cells are critical for expressing proteins with appropriate folding, assembly, and post-translational modifications, which are required for therapeutic efficacy and safety.
Based on Molecule, the market is segmented into Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins and Others. The vaccines segment is estimated to dominate the single-use bioreactors market owing to the global emphasis on immunization programmes and the rapid development of vaccines, as evidenced by the urgent manufacture of the COVID-19 vaccine. Single-use bioreactors provide significant benefits for vaccine production, including increased flexibility in scaling operations, a lower risk of cross-contamination, and faster turnaround times for vaccine development and manufacturing.
Based on End-User, the market is divided into Pharmaceutical & Biopharmaceutical Industries, Contract Research Organizations (CROs) and Others. The pharmaceutical & biopharmaceutical industries segment is estimated to dominate the market over the forecast period. This dominance is due to the substantial role these industries play in biopharmaceutical research, development, and manufacture, which includes vaccines, monoclonal antibodies, and other biologics. The rising frequency of chronic diseases and the desire for personalized medicine have contributed to an increase in the use of single-use bioreactors.
Based on Geography, the single-use bioreactors market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is expected to dominate the single-use bioreactors market during the forecast period. North America, particularly the United States, has a highly developed biopharmaceutical sector that is at the forefront of biologics and vaccine invention and production worldwide. This thriving industry generates enormous demand for single-use bioreactors, which are critical for the efficient and adaptable manufacturing procedures required by modern biopharmaceutical production.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.